Suggestions welcome.
Is Checkmate 650 Trial Over??? Any ... - Advanced Prostate...
Is Checkmate 650 Trial Over??? Any insights? My friend needs some guidance.
Some results have been reported.
newswise.com/articles/combi...
Primary completion date isn’t for 2 years. Still recruiting.
Tall Allen Can you give a little more feedback have you heard anything more
Tall Allen Can you give a little more feedback have you heard anything more ,Do you know of any locations
If you scroll down to "locations" it lists 46 locations worldwide (8 in the US) that are still recruiting. It also has contact info.
clinicaltrials.gov/ct2/show...
They have published early results:
cell.com/cancer-cell/fullte...
Given the small subset of responders and the high toxicity, my opinion is that this would not be my first choice for a clinical trial, unless you know from a tumor biopsy that you have a high mutational burden.
cancernetwork.com/view/phas...
Looks like they are changing dosing and timing to help with toxicity.
Hopefully, that will help. Still it only has benefit in a small subset of patients.
Four people had complete responses. Small number but boy they must be happy! We are looking into this trial as there is one recruiting close to us. Thank you for your input as always.
4 out of 62 - and that was with limited f/u (will even those 4 be sustained beyond a year?). There are many early phase clinical trials that do better. Where are you located?
TA we are in Massachusetts and go to Dana-Farber. We have not been totally happy with our doctor and are finally able to switch over to a new doctor this Wednesday. We are going to see Dr. Beltran. I have typed up a list of points that we want to discuss and have faxed them over to her. Number one on the list is this checkmate trial.We are going to explore all options I’m hoping. My brothers other option at this point is radium 223. He is young at 58. He has failed both Zytiga and Xtandi has done Provenge and started his regime with chemo two years ago. His prostate was radiated by Dr. Anthony D’Amico at Brigham and women’s. He went for a bone biopsy to look at DNA but couldn’t get enough tissue. He went to foundation one and just received results from them with two AR mutations. We are running out of options. We have looked into Veyonda but only being done in Australia for prostate cancer. He is also looking at BAT at John Hopkins with Dr. Sam Denmeade as recommended by Nal. My brother has extensive bone Mets but no soft tissue. The cancer has been held at bay but is now beginning to move. He went through chemo (Docetaxel) easily the first time. This research has become a full-time job and my head is spinning. Thank the Lord for this wonderful forum and all the help it has provided us. Your input is always welcome and so valuable.
There are many clinical trials I would pursue ahead of this one. Why pursue a trial that had such poor results so far? How about the BiTE trials, or the CAR-T trials (listed at the end of this). HPN 424 is at Mass General.
prostatecancer.news/2019/12...
There are also several trials of radiopharmaceuticals in the US.
prostatecancer.news/2020/08...
I would certainly pursue the trial of Lu-177-PSMA-617 with Keytruda at UCSF before the Checkmate 650 trial.
There are many many clinical trials out there. I think the BET inhibitor trials are especially worth looking at when there are AR mutations.
If he has painful bone metastases (which is a requirement for Ra 223), he is not a candidate for BAT.
Veyonda results were no better than trials without the radiosensitizer; but more trials are needed.
There are many great medical oncologists in Boston. Dr Beltran specializes in neuroendocrine differentiation, which your brother does not have.
cancernetwork.com/view/sumi...
Also TA Dr Sharma reports that one of the two men in remission has gone four years from start and the other three years. I’ve included the video where he discusses more of this trial.
It is always wonderful to hear about exceptional remissions. Just keep in mind how rare that was - the likelihood of you getting those results are very small. Also, evaluate it in context of many other trials that saw similar rates of exceptional remissions. This one has become top-of-mind for you because you are focussed on it for some reason. You are far better off betting on the average outcome than the longshot.
It appears as recruiting
clinicaltrials.gov/ct2/show...
Thank you tango, we have checked it out and looks like they are recruiting close to where we live. Definitely going to look into this
Discuss extensively possible side effects, The preliminary results indicate that about 25% of the patients responded to treatment and about 40 to 50% had grade 3 to 5 adverse events.
ctep.cancer.gov/protocoldev...
ascopost.com/issues/april-1...
Best of luck on this journey.!